

Orazio Caffo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1421898/publications.pdf>

Version: 2024-02-01

209
papers

4,741
citations

109321

35
h-index

123424

61
g-index

211
all docs

211
docs citations

211
times ranked

5699
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.. Journal of Clinical Oncology, 1994, 12, 454-466.	1.6	435
2	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trialâ€”FIRSTANA. Journal of Clinical Oncology, 2017, 35, 3189-3197.	1.6	251
3	High syndecanâ€”1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer, 2003, 98, 474-483.	4.1	205
4	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer, 2004, 91, 1996-2004.	6.4	158
5	Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.. Journal of Clinical Oncology, 1994, 12, 2094-2101.	1.6	155
6	Pain and Quality of Life after Surgery for Breast Cancer. Breast Cancer Research and Treatment, 2003, 80, 39-48.	2.5	146
7	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Frontiers in Pharmacology, 2016, 7, 376.	3.5	127
8	Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer, 2010, 68, 264-268.	2.0	107
9	p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. British Journal of Cancer, 1996, 74, 208-215.	6.4	105
10	Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma ? results of a multiparametric study. Breast Cancer Research and Treatment, 1995, 36, 205-217.	2.5	102
11	Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma: A survey by a self-administered questionnaire. , 1996, 78, 1089-1097.		97
12	Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up. Human Pathology, 1996, 27, 1149-1155.	2.0	94
13	c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinomaâ€”an immunocytochemical study. European Journal of Cancer, 1994, 30, 16-22.	2.8	74
14	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. European Urology, 2015, 68, 147-153.	1.9	73
15	Cyclin-d1-gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 immunohistochemical expression. , 1997, 74, 171-174.		66
16	p27kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. International Journal of Cancer, 2000, 89, 236-241.	5.1	62
17	Radiosensitization with chemotherapeutic agents. Lung Cancer, 2001, 34, 81-90.	2.0	54
18	Pain after Quadrantectomy and Radiotherapy for Early-Stage Breast Cancer: Incidence, Characteristics and Influence on Quality of Life. Oncology, 2003, 65, 23-28.	1.9	54

#	ARTICLE	IF	CITATIONS
19	Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 498-506.	4.4	54
20	Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors. <i>Urology</i> , 2012, 79, 644-649.	1.0	50
21	Concurrent adjuvant chemotherapy and immediate breast reconstruction with skin expanders after mastectomy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 60, 267-275.	2.5	49
22	Long-term Cosmetic Outcome and Toxicity in Patients Treated with Quadrantectomy and Radiation Therapy for Early-Stage Breast Cancer. <i>Oncology</i> , 1995, 52, 177-181.	1.9	48
23	Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. <i>Annals of Oncology</i> , 1996, 7, 695-703.	1.2	48
24	Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015, 115, 744-752.	2.5	47
25	Bax immunohistochemical expression in breast carcinoma: A study with long term follow-up. , 1998, 79, 13-18.		45
26	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0158952.	2.5	45
27	Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 1310-1316.	0.8	44
28	Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial. <i>Journal of Thoracic Oncology</i> , 2007, 2, 221-229.	1.1	42
29	First-Line PAZopanib in Non-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e609-e614.	1.9	42
30	Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 165-175.e2.	1.9	41
31	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018, 19, 93-104.	2.6	41
32	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 70, 67-74.	7.7	41
33	Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. <i>Journal of Neuro-Oncology</i> , 2012, 107, 191-196.	2.9	40
34	Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5006-5006.	1.6	40
35	Evaluation of sexual life after orchidectomy followed by radiotherapy for early-stage seminoma of the testis. <i>BJU International</i> , 2001, 83, 462-468.	2.5	37
36	Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. <i>Lancet</i> , The, 1999, 353, 1310-1314.	13.7	36

#	ARTICLE	IF	CITATIONS
37	Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase II trials. <i>Radiotherapy and Oncology</i> , 2016, 121, 193-198.	0.6	36
38	Ten-year results of treatment of ductal carcinoma in situ (DCIS) of the breast with conservative surgery and radiotherapy. <i>European Journal of Cancer</i> , 1997, 33, 1559-1565.	2.8	35
39	Ocular metastases from breast carcinoma: A multicentric retrospective study.. <i>Oncology Reports</i> , 2000, 7, 761-5.	2.6	35
40	Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. <i>Frontiers in Pharmacology</i> , 2016, 7, 123.	3.5	35
41	Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?. <i>World Journal of Urology</i> , 2015, 33, 1079-1085.	2.2	34
42	Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. <i>Lung Cancer</i> , 1998, 22, 31-38.	2.0	33
43	Prognostic value of thymidine phosphorylase expression in breast carcinoma. <i>International Journal of Cancer</i> , 2002, 97, 512-517.	5.1	33
44	On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. <i>Annals of Oncology</i> , 2020, 31, 1415-1416.	1.2	32
45	Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 258-258.	1.6	32
46	Recurrent Prostate Cancer Genomic Alterations Predict Response to Brachytherapy Treatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 594-600.	2.5	31
47	Serial ¹⁸ F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. <i>Future Oncology</i> , 2016, 12, 333-342.	2.4	31
48	Quality of life in patients with ductal carcinoma in situ of the breast treated with conservative surgery and postoperative irradiation. <i>Breast Cancer Research and Treatment</i> , 1999, 54, 109-115.	2.5	30
49	Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. <i>BJU International</i> , 2008, 102, 1080-1085.	2.5	30
50	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019, 74, 35-42.	7.7	30
51	Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. <i>Cancer</i> , 2011, 117, 1190-1196.	4.1	29
52	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 733-737.	1.1	28
53	Management of metastatic castration-resistant prostate cancer: A focus on radium-223. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 43-51.	4.4	28
54	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e223-e231.	1.9	27

#	ARTICLE	IF	CITATIONS
55	Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2008, 43, 216-223.	1.6	25
56	Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. <i>Journal of Neuro-Oncology</i> , 2013, 111, 163-167.	2.9	25
57	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018, 1, 467-475.	5.4	25
58	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015, 75, 1329-1338.	2.3	24
59	Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103351.	4.4	24
60	Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience. <i>Annals of Oncology</i> , 2009, 20, 349-352.	1.2	23
61	Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. <i>Future Oncology</i> , 2014, 10, 985-993.	2.4	23
62	Biochemical and Objective Response to Abiraterone Acetate Withdrawal: Incidence and Clinical Relevance of a New Scenario for Castration-resistant Prostate Cancer. <i>Urology</i> , 2013, 82, 1090-1093.	1.0	22
63	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22
64	Impact of Enzalutamide Administration on Primary Prostate Cancer Volume: A Metabolic Evaluation by Choline Positron Emission Tomography in Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 312-316.	1.9	21
65	Quality of Life in Patients with Early Stage Breast Carcinoma Treated with Conservation Surgery and Radiotherapy. An Italian Monoinstitutional Study. <i>Tumori</i> , 2001, 87, 78-84.	1.1	20
66	Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. <i>BJU International</i> , 2011, 108, 1825-1832.	2.5	20
67	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e1-240.e11.	1.6	20
68	p21 Expression in colorectal carcinomas: a study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999, 435, 559-565.	2.8	19
69	Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 124-129.	4.4	19
70	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>European Urology Oncology</i> , 2020, 3, 176-182.	5.4	19
71	Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 31-37.	0.8	18
72	Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 152-156.	1.6	18

#	ARTICLE	IF	CITATIONS
73	Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 140, 140-146.	2.8	18
74	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	2.5	17
75	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016, 7, 40085-40094.	1.8	17
76	BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. <i>Lung Cancer</i> , 2016, 95, 73-81.	2.0	16
77	Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up. <i>British Journal of Cancer</i> , 1998, 77, 1661-1668.	6.4	15
78	Trimodality treatment in the conservative management of infiltrating bladder cancer: A critical review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 176-190.	4.4	15
79	Cardiovascular toxicities of systemic treatments of prostate cancer. <i>Nature Reviews Urology</i> , 2017, 14, 230-243.	3.8	15
80	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	3.7	15
81	Evaluation of Toxicity and Quality of Life Using a Diary Card During Postoperative Radiotherapy for Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 459-465.	1.3	14
82	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 48-55.	1.9	14
83	Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. <i>Future Oncology</i> , 2018, 14, 431-442.	2.4	14
84	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	1.9	14
85	Physical side effects and quality of life during postoperative radiotherapy for uterine cancer. prospective evaluation by a diary card. <i>Gynecologic Oncology</i> , 2003, 88, 270-276.	1.4	13
86	Quality of life after radiotherapy for early-stage testicular seminoma. <i>Radiotherapy and Oncology</i> , 2001, 59, 13-20.	0.6	12
87	A Phase II Study of Liposomal Doxorubicin in Recurrent Epithelial Ovarian Carcinoma. <i>Tumori</i> , 2004, 90, 556-561.	1.1	12
88	Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1197-1202.	2.3	12
89	Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario. <i>Future Oncology</i> , 2012, 8, 1585-1595.	2.4	12
90	Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study. <i>Radiation Oncology</i> , 2012, 7, 177.	2.7	12

#	ARTICLE	IF	CITATIONS
91	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	2.4	12
92	Cytometric DNA Analysis and Prognostic Biomarkers in Breast Carcinoma. Expression of P53 Product in the Different Ploidy Classes. <i>Analytical Cellular Pathology</i> , 1997, 15, 31-45.	2.1	11
93	Subclinical Ductal Carcinoma in Situ of the Breast: Treatment with Conservative Surgery and Radiotherapy. <i>Tumori</i> , 1999, 85, 488-493.	1.1	11
94	Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 107, 186-195.	2.8	11
95	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	1.9	11
96	p21WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment. <i>European Journal of Cancer</i> , 1996, 32, 2182-2183.	2.8	10
97	An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1037-1051.	3.3	10
98	Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 965-973.	2.4	10
99	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 255-263.	3.8	10
100	Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2018, 97, 41-48.	2.8	9
101	Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 71.	3.7	9
102	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1115-1123.	2.4	9
103	Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 19-28.	2.9	8
104	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	2.4	8
105	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021, 155, 56-63.	2.8	8
106	Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation. <i>Drugs in Context</i> , 2018, 7, 1-5.	2.2	8
107	Treatment sequencing in oncology: balancing clinical trial and real-world evidence. <i>Future Oncology</i> , 2019, 15, 2887-2889.	2.4	7
108	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 654-660.	3.9	7

#	ARTICLE	IF	CITATIONS
109	Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2633-2638.	6.4	7
110	Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study. <i>Radiation Oncology</i> , 2015, 10, 130.	2.7	6
111	Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e15-265.e21.	1.6	6
112	Splice variants of androgen receptor and prostate cancer. <i>Oncology Reviews</i> , 2016, 10, 297.	1.8	6
113	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017, 77, 1012-1019.	2.3	6
114	Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?. <i>Nature Reviews Urology</i> , 2017, 14, 575-575.	3.8	6
115	Sequencing strategies in the new treatment landscape of prostate cancer. <i>Future Oncology</i> , 2019, 15, 2967-2982.	2.4	6
116	Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. <i>Cancers</i> , 2020, 12, 1131.	3.7	6
117	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	3.6	6
118	Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5089-5089.	1.6	6
119	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 148-148.	1.6	6
120	Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103491.	4.4	6
121	The Role of Brachytherapy in the Management of Oropharyngeal Carcinomas: The Trento Experience. <i>Tumori</i> , 2002, 88, 137-141.	1.1	5
122	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. <i>European Urology Supplements</i> , 2009, 8, 738-746.	0.1	5
123	Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 953-957.	2.5	5
124	Metabolic and Prostate-Specific Antigen Response After Abiraterone Acetate Withdrawal: A New Clinical Scenario for Castration-Resistant Prostate Cancer?. <i>Clinical Genitourinary Cancer</i> , 2013, 11, e10-e14.	1.9	5
125	Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 180-186.	1.6	5
126	Is It Possible That One Patient May Again Experience a Response to Abiraterone Acetate Withdrawal During an Abiraterone Acetate Rechallenge?. <i>European Urology</i> , 2014, 66, 179-180.	1.9	5

#	ARTICLE	IF	CITATIONS
127	Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 899-908.	1.8	5
128	Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. European Journal of Cancer, 2020, 125, 153-163.	2.8	5
129	Long-term outcomes and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) showing abiraterone withdrawal syndrome (AWS) after docetaxel (DOC) treatment.. Journal of Clinical Oncology, 2016, 34, 324-324.	1.6	5
130	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. Journal of Clinical Oncology, 2017, 35, 5030-5030.	1.6	5
131	Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis.. Journal of Clinical Oncology, 2018, 36, 323-323.	1.6	5
132	Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?. Current Drug Targets, 2016, 17, 1301-1308.	2.1	5
133	Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome?. European Urology, 2016, 70, 898-899.	1.9	4
134	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
135	Biological Characterisation of Superficial Bladder Cancer by Bivariate Cytokeratin 7/DNA Analysis, Flow Cytometric Assessment of MIB-1, and an Immunohistochemical Study. Analytical Cellular Pathology, 2000, 21, 21-33.	2.1	3
136	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. Future Oncology, 2018, 14, 2691-2699.	2.4	3
137	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. Journal of Clinical Medicine, 2020, 9, 1950.	2.4	3
138	Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature. Future Oncology, 2021, 17, 597-609.	2.4	3
139	p27kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. International Journal of Cancer, 2000, 89, 236-241.	5.1	3
140	P-548 Prolonged infusion (PI) of gemcitabine (G) in combination with cisplatin (C) in patients with advanced non-small cell lung cancer (NSCLC): preliminary results of a dose-finding and pharmacokinetic (PK) study. Lung Cancer, 2003, 41, S230.	2.0	2
141	A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 369-375.	2.3	2
142	Gastrointestinal metastases from prostate cancer: a review of the literature. Future Oncology, 2015, 11, 691-702.	2.4	2
143	Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer. Anti-Cancer Drugs, 2017, 28, 654-659.	1.4	2
144	Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies' agenda. Tumori, 2019, 105, 161-167.	1.1	2

#	ARTICLE	IF	CITATIONS
145	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. Expert Review of Anticancer Therapy, 2021, 21, 389-400.	2.4	2
146	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 391-396.	1.0	2
147	Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab. Immunotherapy, 2021, 13, 1093-1103.	2.0	2
148	Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries. European Urology Oncology, 2021, 4, 1011-1012.	5.4	2
149	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. Journal of Clinical Oncology, 2014, 32, 92-92.	1.6	2
150	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2015, 33, e16059-e16059.	1.6	2
151	First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study.. Journal of Clinical Oncology, 2016, 34, e16081-e16081.	1.6	2
152	Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5033-5033.	1.6	2
153	Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.. Journal of Clinical Oncology, 2018, 36, 209-209.	1.6	2
154	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World Journal of Clinical Oncology, 2021, 12, 1037-1046.	2.3	2
155	A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training&Validation Trial. Journal of Medical Internet Research, 2022, 24, e27349.	4.3	2
156	A Model-Based Framework to Identify Optimal Administration Protocols for Immunotherapies in Castration-Resistance Prostate Cancer. Cancers, 2022, 14, 135.	3.7	2
157	MP24-13 WITHDRAWN: RECURRENT PROSTATE CANCER GENOMIC ALTERATIONS PREDICT RESPONSE TO BRACHYTHERAPY TREATMENT. Journal of Urology, 2014, 191, .	0.4	1
158	Unusual small bowel metastatic localization in a castration-resistant prostate cancer patient. Clinical Practice (London, England), 2014, 11, 559-562.	0.1	1
159	Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:1475. European Urology. 2015. 68. e132-e133.	1.9	1
160	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. Cancers, 2019, 11, 1908.	3.7	1
161	Nasopharyngeal swab or clinical-radiological evidence: the dark side of the moon for cancer patients in the COVID-19 era. Future Oncology, 2020, 16, 1321-1322.	2.4	1
162	Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. Future Oncology, 2021, 17, 807-815.	2.4	1

#	ARTICLE	IF	CITATIONS
163	Weekly paclitaxel (wPCT) for pretreated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Updated data from a single institution experience in the daily clinical practice.. Journal of Clinical Oncology, 2014, 32, e19143-e19143.	1.6	1
164	Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.. Journal of Clinical Oncology, 2014, 32, 253-253.	1.6	1
165	Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).. Journal of Clinical Oncology, 2015, 33, e16017-e16017.	1.6	1
166	Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers.. Journal of Clinical Oncology, 2018, 36, 322-322.	1.6	1
167	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. Journal of Clinical Oncology, 2019, 37, e16013-e16013.	1.6	1
168	Looking to possible predictive factors of primary resistance to abiraterone acetate (AA) and enzalutamide (ENZ) in pretreated patients (pts) with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, 248-248.	1.6	1
169	Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis. Joint Bone Spine, 2022, 89, 105403.	1.6	1
170	Radiochemotherapy for Non Small Cell Lung Cancer. Current Drug Therapy, 2010, 5, 180-191.	0.3	0
171	2-weekly docetaxel: issues for clinical practice. Cancer Biology and Therapy, 2015, 16, 17-18.	3.4	0
172	148P: Concordance between detection of EGFR mutations on tissue and in circulating free tumor DNA (cftDNA) in newly diagnosed metastatic lung adenocarcinoma (mLA). Journal of Thoracic Oncology, 2016, 11, S122.	1.1	0
173	Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation. Prostate International, 2016, 4, 54-55.	2.3	0
174	PD4-2-5: Prolonged infusion (PI) of gemcitabine (G) in combination with cisplatin (C) in patients with advanced non-small cell lung cancer (NSCLS): preliminary results of measurement of g and its metabolites in plasma and white blood cells (WBC). Journal of Thoracic Oncology, 2007, 2, S452.	1.1	0
175	Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial).. Journal of Clinical Oncology, 2012, 30, 220-220.	1.6	0
176	Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.. Journal of Clinical Oncology, 2013, 31, 90-90.	1.6	0
177	Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.. Journal of Clinical Oncology, 2013, 31, 208-208.	1.6	0
178	Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. Journal of Clinical Oncology, 2014, 32, 214-214.	1.6	0
179	Metabolic response by choline positron emission tomography (cPET) to enzalutamide (ENZ) in castration-resistant prostate cancer (CRPC) patients (pts): Preliminary results of a monoinstitutional prospective study.. Journal of Clinical Oncology, 2014, 32, 76-76.	1.6	0
180	Volume reduction and metabolic response of primary prostate cancer to enzalutamide (ENZ) : A metabolic evaluation by 18F-fluorocholine-positron emission tomography/computerized tomography (18F-FCH PET/CT) in castration resistant prostate cancer (CRPC) patients (pts).. Journal of Clinical Oncology, 2014, 32, e16056-e16056.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Potential value of rapid prostate-specific antigen (PSA) decline, in identifying primary resistance (PRes) to abiraterone acetate (AA) and enzalutamide (ENZ), in pre-treated castration resistant prostate cancer (CRPC) patients (pts).. Journal of Clinical Oncology, 2014, 32, e16044-e16044.	1.6	0
182	Metabolic response to enzalutamide (ENZ), assessed by choline positron emission tomography (cPET), in castration resistant prostate cancer (CRPC) patients (pts): Updated results of a monoinstitutional prospective study.. Journal of Clinical Oncology, 2014, 32, e16043-e16043.	1.6	0
183	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.. Journal of Clinical Oncology, 2015, 33, 216-216.	1.6	0
184	Concurrent gemcitabine (GEM) and radiotherapy (XRT) as organ-sparing treatment for muscle-infiltrating bladder cancer (MIBC): Preliminary results of a patient-based cumulative analysis of seven phase I-II trials.. Journal of Clinical Oncology, 2015, 33, 306-306.	1.6	0
185	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.. Journal of Clinical Oncology, 2015, 33, 213-213.	1.6	0
186	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. Journal of Clinical Oncology, 2015, 33, 206-206.	1.6	0
187	Abstract P5-21-06: Clinical outcomes according to pathological complete response (pCR) and proliferation index of residual tumor (RT) after neoadjuvant chemotherapy (NC) in invasive breast cancer (IBC)., 2015,, .		0
188	Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).. Journal of Clinical Oncology, 2015, 33, e16045-e16045.	1.6	0
189	Neoadjuvant chemotherapy (NC) in invasive breast cancer (IBC) subtypes: Outcomes according to pathological complete response (pCR) and proliferation index (PI) of residual tumor (RT).. Journal of Clinical Oncology, 2015, 33, e12027-e12027.	1.6	0
190	Prognostic factors in muscle-infiltrating bladder cancer (MIBC) treated with an organ-sparing treatment with concurrent gemcitabine (GEM) and radiotherapy (XRT): Results of a patient-based cumulative analysis of seven phase I-II trials.. Journal of Clinical Oncology, 2015, 33, e15529-e15529.	1.6	0
191	Does abiraterone withdrawal syndrome (AWS) exist also in metastatic castration-resistant prostate cancer (mCRPC) first-line setting?.. Journal of Clinical Oncology, 2016, 34, 344-344.	1.6	0
192	Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.. Journal of Clinical Oncology, 2016, 34, 210-210.	1.6	0
193	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.. Journal of Clinical Oncology, 2016, 34, 325-325.	1.6	0
194	Clinicians' attitudes and preferences in choosing the first line drug for metastatic castration resistant prostate cancer (mCRPC): Preliminary results from a multicenter Italian study after the introduction of abiraterone acetate (AA) in the clinical practice.. Journal of Clinical Oncology, 2016, 34, 332-332.	1.6	0
195	Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 231-231.	1.6	0
196	Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.. Journal of Clinical Oncology, 2016, 34, 326-326.	1.6	0
197	Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor to predict overall survival.. Journal of Clinical Oncology, 2016, 34, 219-219.	1.6	0
198	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study.. Journal of Clinical Oncology, 2016, 34, 211-211.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.. Journal of Clinical Oncology, 2016, 34, 342-342.	1.6	0
200	Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).. Journal of Clinical Oncology, 2016, 34, e16569-e16569.	1.6	0
201	Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. Journal of Clinical Oncology, 2017, 35, e585-e585.	1.6	0
202	Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. Journal of Clinical Oncology, 2017, 35, 254-254.	1.6	0
203	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study.. Journal of Clinical Oncology, 2017, 35, 230-230.	1.6	0
204	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.. Journal of Clinical Oncology, 2017, 35, e16521-e16521.	1.6	0
205	Treatment and clinical outcomes of very elderly (≥ 80 yrs) metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-institution retrospective analysis.. Journal of Clinical Oncology, 2018, 36, 327-327.	1.6	0
206	Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).. Journal of Clinical Oncology, 2018, 36, 5026-5026.	1.6	0
207	PAZopanib as first line in MEtastatic RCC patients: A real-world Italian experience (PAMERIT) Tj ETQq1 1 0.784314 rgBT /Overl	1.6	0
208	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. Journal of Clinical Oncology, 2019, 37, 5050-5050.	1.6	0
209	Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). Tumori, 2013, 99, 35-8.	1.1	0